Live Breaking News & Updates on Oncology Congress

Stay updated with breaking news from Oncology congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER" ....

Mccormick Place , United States , Phil Lhuilier , Ignacio Melero Bermejo , Catalym Gmb , Alison Opalko , Trophic Communications , Oncology Congress , American Society Of Clinical Oncology , Ted Human Effector Cell Relocation Phase , American Society , Clinical Oncology , Annual Meeting , Growth Differentiation , Presentation Details , Universidad De Navarra , Demand Mccormick Place , Ted Human Effector , Relocation Phase , Phill Huilier , Stephanie May , Ihr Portfolio ,

FDA Grants Orphan Drug Designation to LYT-200 in AML

The FDA has granted orphan drug designation to LYT-200 for the treatment of acute myeloid leukemia. ....

United States , Amir Fathi , Aleksandra Filipovic , Leukemia Program At Massachusetts , Puretech Health , Oncology Congress , International Prognostic Scoring System , Leukemia Program , Massachusetts General Hospital ,

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

29.02.2024 - Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role . Seite 1 ....

Saqib Islam , European Society For Medical Oncology Congress , European Union , Chief Executive Officer , New England Journal , Presidential Symposium , European Society , Oncology Congress ,

Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab. ....

New York , United States , Thomas Marron , Oncology Congress , Tisch Cancer Institute , Icahn School Of Medicine At Mount Sinai , Icahn School , Mount Sinai , Esmo Immuno Oncology Congress ,

Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma

Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors. ....

Iovance Biotherapeutics , Bristol Myers Squibb , Merck Serono , Martin Wermke , Oncology Congress , University Hospital Carl Gustav Carus , Drug Administration , Society For Immunotherapy Of Cancer , Early Clinical Trial Unit , National Center , Tumor Diseases Dresden , Prescription Drug User Fee Act , Ln 144 , Phase 2c 144 01 Trial Nct02360579 ,